乳腺癌血管生成拟态和免疫微环境关系的初步探索

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1461 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To understand the relationship between the clinicopathological features of breast cancer and the expression of vasculogenic mimicry (VM ) and CD8+T cells. Futher to explore the correlation between VM and immune microenvironment. Methods 60 cases of breast cancer tissue samples were collected to make tissue chip. The expression of VM was detected by CD31/PAS double staining. IHC was used to assess the expression of CD8⁺T cells.The relationship among VM expression, CD8⁺T cell expression and clinicopathological characteristics were analyzed, so as to infer the relationship between VM and CD8⁺T cells. Results Among 60 cases of breast cancer tissue samples, VM was detected in 24 cases (40%). The positive rate of VM in pathlogical grade G3 was 63.2%, while it was 29.3% in tissues from G1 and G2. The difference was statistically significant (χ²=6.213,P=0.013).The positive detection rate of VM in stage Ⅲ (54.5%) was significantly higher than that in stage Ⅰ/Ⅱ (χ²=6.231,P=0.044). The positive expression of VM in triple negative type was significantly higher than that in other molecular types, and the difference was statistically significant (χ²=14.0,P＜0.001).There was no significant difference in the detection rate of VM with age and histological types.The positive expression of CD8⁺T cells was detected in 26 cases (43.3%). The positive expression of CD8⁺T cells in triple negative breast cancer (TNBC) was significantly lower than that in other molecular subtypes, and the difference was statistically significant (χ²=7.454,P=0.006). There was no significant difference in the expression of CD8⁺ T cells among age, histological type, pathological grade and clinical stage. There was a significant difference in the expression of CD8⁺ T cells between VM negative and positive in the whole samples (χ²=11.584,P＜0.001), but there was no significant difference in TNBC samples (χ²=1.313,P=0.252). Conclusion VM formation is more common in advanced and poorly differentiated breast cancer, especially in TNBC, and CD8⁺T cells are more common in non-TNBC. In breast cancer with significant VM formation, CD8⁺T lymphocytes are often less.

Key words： breast cancer vasculogenic mimicry tumor immune microenvironment CD8⁺T lymphocytes

Received: 12 September 2024

ZTFLH:

R737

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HUANG Jing
	LUAN Feiyang
	MA Xinyue
	AN Yiyang
	HU Sirui
	LIU Xi
	YANG Jin
	DONG Danfeng

Cite this article:

HUANG Jing,LUAN Feiyang,MA Xinyue等. Preliminary exploration of the relationship between vasculogenic mimicry and immune microenvironment in breast cancer[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2025, 36(1): 16-20.

URL:

https://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR https://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2025/V36/I1/16

[1]	Siegel R L,Giaquinto A N,Jemal A.Cancer statistics, 2024[J].CA Cancer J Clin,2024,74(1):12-49.
[2]	郑荣寿,陈茹,韩冰峰,等.2022年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志,2024,46(3):221-231.?
[3]	Bejarano L,Jordāo M J C,Joyce J A.Therapeutic targeting of the tumor microenvironment[J].Cancer Discov,2021,11(4):933-959.
[4]	Murai T,Matsuda S.Targeting the PI3K-Akt-mTOR signaling pathway involved in vasculogenic mimicry promoted by cancer stem cells[J].Am J Cancer Res,2023,13(11):5039-5046.
[5]	Chavoshi H,Poormolaie N,Vahedian V,et al.Vascular mimicry: a potential therapeutic target in breast cancer[J].Pathol Res Pract,2022,234:153922.
[6]	Zhang L,Wu J,Yin W W,et al.Vasculogenic mimicry-associated novel gene signature predicted prognosis and response to immunotherapy in lung adenocarcinoma[J].Pathol Res Pract,2024,253:155048.
[7]	Lv B,Wang Y,Ma D,et al.Immunotherapy: reshape the tumor immune microenvironment[J].Front Immunol,2022,13:844142.
[8]	Murugesan A,Bharath C,Balakrishnan S,et al.Expression of HIF-1α and nestin in oral squamous cell carcinoma and its association with vasculogenic mimicry[J].J Cancer Res Ther,2024,20(1):176-180.
[9]	Hoxha I,Sadiku F,Hoxha L,et al.Breast cancer and lifestyle factors: umbrella review[J].Hematol Oncol Clin North Am,2024,38(1):137-170.
[10]	Liu Y, He X, Yang Y I. Tumor immune microenvironment-based clusters in predicting prognosis and guiding immunotherapy in breast cancer[J].J Biosci,2024,49(4):19.
[11]	徐可佩,方晓政,林怡,等.MRI影像组学与乳腺癌肿瘤新生血管相关性研究[J].磁共振成像,2022,13(8):146-149.
[12]	Wei X,Chen Y, Jiang X,et al.Mechanisms of vasculogenic mimicry in hypoxic tumor microenvironments[J].Mol Cancer,2021,20(1):7.
[13]	Morales-Guadarrama G,Méndez-Pérez E A,García-Quiroz J,et al.The inhibition of the FGFR/PI3K/Akt Axis by AZD4547 disrupts the proangiogenic microenvironment and vasculogenic mimicry arising from the interplay between endothelial and triple-negative breast cancer cells[J].Int J Mol Sci,2023,24(18):13770.
[14]	Jung E,Lee Y H, Ou S,et al.EGR1 regulation of vasculogenic mimicry in the MDA-MB-231 triple-negative breast cancer cell line through the upregulation of KLF4 expression[J].Int J Mol Sci,2023,24(18):14375.
[15]	Wu S Y,Xu Y,Chen L,et al.Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the Future-C-Plus trial[J].Mol Cancer,2022,21(1):84.
[16]	Lin F,Ke Z B, Xue Y T,et al.A novel CD8+T cell-related gene signature for predicting the prognosis and immunotherapy efficacy in bladder cancer[J].Inflamm Res,2023,72(8):1665-1687.
[17]	Lin X,Long S,Yan C,et al.Therapeutic potential of vasculogenic mimicry in urological tumors[J].Front Oncol,2023,13:1202656.
[18]	Dudley A C,Griffioen A W.Pathological angiogenesis: mechanisms and therapeutic strategies[J].Angiogenesis,2023,26(3):313-347.

[1]	. [J]. Med. J. Chin. Peop. Armed Poli. Forc., 2024, 35(9): 818-822.